Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...

William Blair lifted their Q1 2026 earnings estimates for shares of Ionis Pharmaceuticals in a research note issued on ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Arizona State Retirement System raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 8.8% in the ...